<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840888</url>
  </required_header>
  <id_info>
    <org_study_id>18204</org_study_id>
    <secondary_id>J2J-MC-JZLD</secondary_id>
    <nct_id>NCT04840888</nct_id>
  </id_info>
  <brief_title>A Study of LY3484356 in Healthy Female Participants</brief_title>
  <official_title>Evaluation of the Effect of Food, Omeprazole, Itraconazole, and Rifampicin on the Pharmacokinetics of LY3484356 in Healthy Females of Non-Child-Bearing Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the amount of LY3484356 is found in the blood&#xD;
      stream and how long the body takes to get rid of it when given with and without food, in&#xD;
      healthy females participants of non-childbearing potential. The study will also evaluate the&#xD;
      tolerability and safety of LY3484356 by collecting the information about any side effects&#xD;
      that may occur. The study will last approximately 27 days, not including screening.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 26, 2021</start_date>
  <completion_date type="Anticipated">December 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of LY3484356</measure>
    <time_frame>Predose up to 168 hours postdose</time_frame>
    <description>PK: AUC[0-∞] of LY3484356</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Observed Concentration (Cmax) of LY3484356</measure>
    <time_frame>Predose up to 168 hours postdose</time_frame>
    <description>PK: Cmax of LY3484356</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Time of Maximum Observed Concentration (Tmax) of LY3484356</measure>
    <time_frame>Predose up to 168 hours postdose</time_frame>
    <description>PK: Tmax of LY3484356</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3484356 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 administered as single doses orally with (fed) or without food (fasted).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3484356 + Omeprazole (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 administered as single dose orally on Day 1 and omeprazole administered orally as single dose on Days 5 to 8 followed by a single dose of LY3484356 co-administered with a single dose of omeprazole on Day 9 orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3484356 + Itraconazole (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 administered as single dose orally on Day 1 and itraconazole administered orally as single dose on Days 5 to 9. The single dose of LY3484356 co-administered with a single dose of itraconazole on Day 10 orally followed by single dose of itraconazole administered orally on Days 11 to 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3484356 + Rifampicin (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3484356 administered as single dose orally on Day 1 and rifampicin administered orally as single dose on Days 5 to 11. The single dose of LY3484356 co-administered with a single dose of rifampicin on Day 12 orally followed by single dose of rifampicin administered orally on Days 13 to 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3484356</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3484356 (Cohort 1)</arm_group_label>
    <arm_group_label>LY3484356 + Itraconazole (Cohort 3)</arm_group_label>
    <arm_group_label>LY3484356 + Omeprazole (Cohort 2)</arm_group_label>
    <arm_group_label>LY3484356 + Rifampicin (Cohort 4)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3484356 + Omeprazole (Cohort 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3484356 + Itraconazole (Cohort 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3484356 + Rifampicin (Cohort 4)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical assessment&#xD;
&#xD;
          -  Body mass index (BMI) within the range 18.0 to 35.0 kilograms per meter squared&#xD;
             (kg/m²)&#xD;
&#xD;
          -  Female participants of non childbearing potential. This includes females who are not&#xD;
             pregnant, non-lactating and either: Infertile due to surgical sterilization&#xD;
             (hysterectomy, bilateral oophorectomy or bilateral salpingectomy, bilateral tubal&#xD;
             ligation, or bilateral tubal occlusion), or alternate medical cause/congenital anomaly&#xD;
             (for example, Müllerian agenesis) or postmenopausal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history or presence of cardiovascular (eg, symptomatic bradycardia with resting&#xD;
             heart rate of &lt;60 beats per minute), respiratory, renal, gastrointestinal, endocrine,&#xD;
             hematological, or neurological disorders capable of significantly altering the&#xD;
             absorption, metabolism, or elimination of drugs&#xD;
&#xD;
          -  Show evidence of hepatitis B, evidence of hepatitis C and/or have evidence of human&#xD;
             immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's wort, within 30 days prior&#xD;
             to dosing&#xD;
&#xD;
          -  Use or intend to use medications that inhibit or induce CYP3A4 within 14 days prior to&#xD;
             dosing until completion of the follow-up visit&#xD;
&#xD;
          -  Smoke more than 10 cigarettes or use the equivalent tobacco, smoking-cessation&#xD;
             products, nicotine-containing products, or e cigarettes (nicotine and non nicotine)&#xD;
             per day&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@Lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>386-257-5717</phone>
    </contact>
    <investigator>
      <last_name>Hugh A Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covance Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>808-592-2631</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 1, 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

